

The European Myeloma Network

An overview of the network

History and goals

Important dates

- 2005 creation of the network with a small group
- 2017 new Bylaw of the EMN
- 2019 inclusion of other relevant collaborative groups under the EMN

Our goals

- Perform large, international trials in myeloma and related conditions
- Uniform standards for correlative studies
- Quality control
- Consensus, guidelines and recommendations in Europe
- Platform for analyses and meta-analyses
- Spread knowledge through workshops and meetings



History and goals

Structure

- Pan-European organization, non-profit foundation, academic status
- Dutch law and bylaws
- International Board

Collaboration

- National cooperative groups, like Italy, Netherlands, Spain, Nordic, SAKK, Germany etc
- Individual centers assigned by national groups (IFM)
- Pharmaceutical industry, Diagnostics, Educational partners
- Agencies: FDA, EMA
- Other stakeholders: EHA, ESMO, IMS
- EU projects (Harmony, Predict)



EMN structure 2023

National groups & branches

Regulatory and National Boards



Organization



Young EMN Board (operative)

Dr. Broijl	Dr. Radocha
Dr. Gay	Dr. Krauth
Dr. Popat	Dr. Touzeau
Dr. Gavriatopoulou	Dr. Ocio
Dr. Rasche	Dr. Slordhal
	Dr. Cengiz-Seval

Board of Directors:

Prof. Sonneveld (President)
Prof. Boccadoro (Vice president)
Prof. Dimopoulos (Member)
Prof. Einsele (Member)
Prof. Ludwig (Member)
Prof. San Miguel (Member)
Prof. Cook (Member)
Prof. Hajek (Member)
Prof. Moreau (Member)
Prof. Schjesvold (Member)


Participants:

Open registration to EMN to be included in the projects and trials of the network.

Registration online is required

www.myeloma-europe.org

Organization




President – Vice President – 2 board members (4 years)


- The EB reports to the Board of Directors and prepares actions and proposals, to be approved by the Board.
- The EB is responsible for annual report and meetings. EB members are appointed by the Board.
- This EB will act as main point of contact/interlocutor of the EMN and it will be directly involved in negotiations with third parties



Organization



Headquarters and data center



Trials

The EMN conducts trials in **myeloma** and other rare hematologic conditions: **smoldering myeloma, amyloidosis, plasma cell leukemia**

EMN study code	Main study drug/s	Setting
EMN01	Lenalidomide	Newly diagnosed transplant-ineligible myeloma
EMN02	Bortezomib, Lenalidomide	Newly diagnosed transplant-eligible myeloma
EMN04	Reduced-intensity allogeneic	Relapsed myeloma
EMN07	Carfilzomib, Pomalidomide	Relapsed/Refractory myeloma
EMN09	Carfilzomib, Bendamustine	Relapsed/Refractory myeloma
EMN10	Ixazomib, Bendamustine	Newly diagnosed transplant-ineligible myeloma
EMN11	Carfilzomib, Pomalidomide	Relapsed/Refractory myeloma
EMN12	Carfilzomib, Lenalidomide	Newly diagnosed primary plasma cell leukemia
EMN13	Ixazomib	Relapsed/Refractory myeloma
EMN14	Pomalidomide, Daratumumab	Relapsed/Refractory myeloma
EMN15	Carfilzomib, Lenalidomide	Smoldering myeloma
EMN17	Daratumumab, Bortezomib, Lenalidomide	Newly diagnosed transplant-eligible myeloma
EMN18	Daratumumab, Bortezomib	Newly diagnosed transplant-eligible myeloma
EMN19	Daratumumab, Bortezomib	Extramedullary disease
EMN20	Carfilzomib, Lenalidomide	Newly diagnosed transplant-ineligible myeloma
EMN22	Daratumumab	Newly diagnosed patients with stage 3B light chain AL amyloidosis
EMN23	Retrospective, observational	Patients with systemic AL amyloidosis in Europe
EMN24	Isatuximab, Carfilzomib, Lenalidomide	Newly Diagnosed transplant-eligible myeloma
EMN26	Iberdomide	Phase 2, maintenance therapy
EMN27	Belantamab Mafodotin	Relapsed/refractory AL amyloidosis
EMN28	Cilta-cel CAR-T	Newly diagnosed transplant-eligible myeloma
EMN29	Selinexor	Relapsed/Refractory myeloma
EMN30	Teclistamab, lenalidomide	Phase 3, newly diagnosed, maintenance post transplant
EMN33	MRD procedures (DaraVRd)	Newly diagnosed transplant-eligible myeloma
EMN34	Elranatamab	Smouldering myeloma
Covid-19	Data collection	Covid-19 MM patients

Protocol Review Committee (scientific & technical) assesses proposals

Many other studies under definition will be available soon



Meetings

Discussion of clinical studies and international events to share knowledge



EMN Trialist Forum

- Annual meeting of the EMN core investigators
- 2-day event in autumn in Baveno – Italy
- Discussion of practical issues, amendments and new proposals under the EMN umbrella

EMN annual meeting

- Annual workshop for all investigators working in the myeloma field
- 3-day 4th EMN Workshop April 2023 in Amsterdam
- Educational sessions, Meet the Experts, Symposia & ~500 attendees (no virtual, after Covid19 pandemic)



Collaborative projects

EMN: an umbrella organization for collaborative groups and projects



HARMONY

A public-private European Network of Excellence - January 2017

Goal: to harness and mine Big Data to speed up the development of improved treatments.

How: Clinical and translational data are merged together in a big database - 53 partners and 32 associated members from 22 countries, including 8 pharma-companies from EFPIA.



HORIZON 2020 European Commission framework - MMPredict project

Goal: to clinically validate a personalized medicine tool that predicts the most effective treatment option in myeloma patients.

How: SkylineDX is developing a microarray-test that can be used for genetic subtyping of myeloma patients → determine the most suitable treatment for patients by predicting their response based on gene expression profiling.



Publications



Review (more underway – to be published in 2023)

- Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos MV, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos MA, Gay F, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Schreder M, Abildgaard N, Hajek R, Zozer N, Kastritis E, Broijl A, Schjesvold F, Boccadoro M, Terpos E. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. *Lancet Haematol*. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7.

ASH – American Society of Hematology

- Efstathios Kastritis, Giovanni Palladini, Meletios-Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C. Minnema, Ashutosh D. Wechalekar, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, and Stefan Schönland. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. Abstract 3244.
- Meral Beksac, Tulin Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H.J. van der Velden, Berna Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, and Evangelos Terpos. Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19). Abstract 4569.

EHA – European Hematology Association

- E. Kastritis. EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK. Abstract P914.
- E. Kastritis. EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK. Abstract P915.

Original article / full paper on clinical trial or other projects

- Schmitz A, Brøndum RF, Johnsen HE, Mellqvist UH, Waage A, Gimsing P, Op Bruinink DH, van der Velden V, van der Holt B, Hansson M, Andersen NF, Frølund UC, Helleberg C, Schjesvold FH, Ahlberg L, Gulbrandsen N, Andreasson B, Lauri B, Haukas E, Bødker JS, Roug AS, Bøgsted M, Severinsen MT, Gregersen H, Abildgaard N, Sonneveld P, Dybkær K. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. *BMC Cancer*. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1.
- D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall'Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Bladé Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, Dürig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hernández Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M, Sonneveld P. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. *J Clin Oncol*. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23.

Contacts

The **EMN** staff is pleased to receive any comment, suggestion or proposal.

E-mail addresses:

info@emn.life

datacenter@emn.life

Website: www.myeloma-europe.org

Big objectives can be achieved only through big collaborations

